In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors.

The Akt kinase family, consisting of three isoforms in humans, is a well-validated class of drug target. Through various screening campaigns in academics and pharmaceutical industries, several promising inhibitors have been developed to date. However, due to the mechanistic and structural similarities of Akt kinases, it is yet a challenging task to discover selective inhibitors against a specific Akt isoform. We here report Akt-selective and also Akt2 isoform-selective inhibitors based on a thioether-macrocyclic peptide scaffold. Several anti-Akt2 peptides have been selected from a library by means of an in vitro display system, referred to as the RaPID (Random nonstandard Peptide Integrated Discovery) system. Remarkably, the majority of these "binding-active" anti-Akt2 peptides turned out to be "inhibitory active", exhibiting IC(50) values of approximately 100 nM. Moreover, these peptides are not only selective to the Akt kinase family but also isoform-selective to Akt2. Particularly, one referred to as Pakti-L1 is able to discriminate Akt2 250- and 40-fold over Akt1 and Akt3, respectively. This proof-of-concept case study suggests that the RaPID system has a tremendous potential for the discovery of unique inhibitors with high family- and isoform-selectivity.

[1]  T. Katoh,et al.  Flexizymes for genetic code reprogramming , 2011, Nature Protocols.

[2]  G. Ning,et al.  The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. , 2011, The Journal of clinical endocrinology and metabolism.

[3]  P. Workman,et al.  Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 , 2010, Molecular Cancer Therapeutics.

[4]  O. Fardel,et al.  Akti-1/2, an allosteric inhibitor of Akt 1 and 2, efficiently inhibits CaMKIα activity and aryl hydrocarbon receptor pathway. , 2010, Chemico-Biological Interactions.

[5]  B. Miao,et al.  Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains , 2010, Proceedings of the National Academy of Sciences.

[6]  B. Brandhuber,et al.  Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition , 2010, PloS one.

[7]  Huan Yang,et al.  The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane , 2010, Cell Death and Differentiation.

[8]  P. Workman,et al.  AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth , 2010, Molecular Cancer Therapeutics.

[9]  G. Bepler,et al.  A Small Molecule Inhibits Akt through Direct Binding to Akt and Preventing Akt Membrane Translocation* , 2010, The Journal of Biological Chemistry.

[10]  Chao Zhang,et al.  Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.

[11]  J. Kahana,et al.  AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. , 2009, Blood.

[12]  H. Murakami,et al.  Ribosomal synthesis of polypeptoids and peptoid-peptide hybrids. , 2008, Journal of the American Chemical Society.

[13]  G. Warren,et al.  Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. , 2008, Journal of medicinal chemistry.

[14]  H. Murakami,et al.  Messenger RNA-programmed incorporation of multiple N-methyl-amino acids into linear and cyclic peptides. , 2008, Chemistry & biology.

[15]  H. Murakami,et al.  Reprogramming the translation initiation for the synthesis of physiologically stable cyclic peptides. , 2008, ACS chemical biology.

[16]  H. Murakami,et al.  Synthesis of polyester by means of genetic code reprogramming. , 2007, Chemistry & biology.

[17]  O. Livnah,et al.  A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. , 2007, Biochemistry.

[18]  P. Cohen,et al.  Assay of protein kinases using radiolabeled ATP: a protocol , 2006, Nature Protocols.

[19]  Hiroshi Murakami,et al.  A highly flexible tRNA acylation method for non-natural polypeptide synthesis , 2006, Nature Methods.

[20]  J. Frahm,et al.  Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis , 2005, Development.

[21]  Yan Shi,et al.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo , 2005, Molecular Cancer Therapeutics.

[22]  C. Arteaga,et al.  Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. , 2005, Cancer research.

[23]  Zhijian Zhao,et al.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[24]  C. Roumestand,et al.  Inhibition of Akt Kinase Activity by a Peptide Spanning the βA Strand of the Proto-oncogene TCL1* , 2004, Journal of Biological Chemistry.

[25]  Andrew D. Hamilton,et al.  Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt , 2004, Cancer Research.

[26]  P. Richardson,et al.  Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. , 2004, Biochemistry.

[27]  E. Sausville,et al.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. , 2003, Molecular cancer therapeutics.

[28]  Brian A. Hemmings,et al.  Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP , 2002, Nature Structural Biology.

[29]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[30]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[31]  Toshiyuki Obata,et al.  Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB* , 2000, The Journal of Biological Chemistry.

[32]  Domenico Coppola,et al.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer , 2000, Oncogene.

[33]  J. Romashkova,et al.  NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.

[34]  B. Hemmings,et al.  A Human Protein Kinase Bγ with Regulatory Phosphorylation Sites in the Activation Loop and in the C-terminal Hydrophobic Domain* , 1999, The Journal of Biological Chemistry.

[35]  J W Szostak,et al.  RNA-peptide fusions for the in vitro selection of peptides and proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y Husimi,et al.  In vitro virus: Bonding of mRNA bearing puromycin at the 3′‐terminal end to the C‐terminal end of its encoded protein on the ribosome in vitro , 1997, FEBS letters.

[37]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[38]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[39]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.